Product Name | Crizotinib hydrochloride | PF-02341066 hydrochloride |
---|---|
CAS | 1415560-69-8 |
Formula | C21H23Cl3FN5O |
MW | 486.80 |
Appearance | Yellow to brown powder |
Storage condition | 4°C, sealed storage, away from moisture |
Crizotinib HCl (formerly known as PF-02341066 hydrochloride; trade name: Xalkori) is a potent, orally bioavailable small molecule inhibitor of c-Met and ALK, with IC50 values of 11 nM and 24 nM in assays involving cells, respectively. In the US, crizotinib is licensed for the treatment of non-small cell lung cancer (NSCLC). It is also being investigated in clinical trials for safety and effectiveness in the treatment of neuroblastoma, anaplastic large cell lymphoma, and other advanced solid tumors in both adults and children. Crizotinib inhibits the activation of the MET signaling pathway and the membrane receptor MET, which in susceptible tumor cell populations may prevent tumor cell growth, migration, invasion, and angiogenesis.
© Copyright 2015-2021 Chemleader Biomedical Co., Ltd. All Rights Reserved.
沪ICP备15046197号-4
沪公网安备31011502007856号
Designed by Kuanersoft